Focus: Humanwell Pharmaceutical is a public specialty pharma company headquartered in Ballwin, Missouri, focused on anesthetic and pain medications with diversified therapeutics across neurology, cardiovascular, endocrinology, oncology, and nephrology.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Humanwell Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Humanwell Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Humanwell Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Flagship product generating 30% of company revenue; expires 2026, creating immediate revenue cliff within 2–3 years.
Extended-release franchise representing $53M revenue; patent expires 2029, creating the company's largest single patent cliff.
Generic ANDA product with sustained $25M revenue in epilepsy; stable cash generator with no exclusivity expiration risk.
Antiarrhythmic ANDA; $22M Part D spend reflects mature, stable market for Class IC antiarrhythmia therapy.
Generic ANDA for bipolar disorder; $16M revenue in psychiatry indication supports diversified CNS presence.
Generic xanthine oxidase inhibitor; $15M revenue in oncology supportive care, stable and low-risk mature market.
Cholinesterase inhibitor ANDA with $3M Part D spend; niche neurology product with limited growth potential as pipeline progresses.
Minor SKU variant of Divalproex bipolar indication; negligible revenue contribution, likely retained for formulary completeness.
Niche epilepsy SKU with de minimis revenue; retained for patient subpopulation labeling and regulatory compliance.
Ultra-low-revenue SKU variant; nominal market presence, likely maintained for formulary/regulatory portfolio breadth.
30 discontinued, 51 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
+28 more products